Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Fruquintinib Combined
With mFOLFOX6/FOLFIRI as the first-line treatment of Metastatic Colorectal Cancer
Phase:
Phase 2
Details
Lead Sponsor:
Zhou Fuxiang
Collaborators:
Henan Cancer Hospital Huangshi Central Hospital, China Hubei Cancer Hospital Xiangya Hospital of Central South University